Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

ClinicalTrials.gov ID: NCT03071224

Public ClinicalTrials.gov record NCT03071224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers

Study identification

NCT ID: NCT03071224
Recruitment status: Completed
Study type: Interventional
Phase: Early Phase 1
Lead sponsor: Invicro; Other
Enrollment: 10 participants

Conditions and interventions

Conditions

Interventions

[18F] MNI-946 Drug
[18F]Florbetapir Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2016
Primary completion: Jun 8, 2021
Completion: Jun 8, 2021
Last update posted: Jun 13, 2021

2016 – 2021

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Invicro	New Haven	Connecticut	06510	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03071224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 13, 2021 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03071224 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →